- Home
- BBU vs AGIO Comparison
BBU vs AGIO Comparison
Compare BBU & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBU
- AGIO
- Stock Information
- Founded
- BBU 2016
- AGIO 2007
- Country
- BBU Bermuda
- AGIO United States
- Employees
- BBU N/A
- AGIO N/A
- Industry
- BBU Engineering & Construction
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- BBU Consumer Discretionary
- AGIO Health Care
- Exchange
- BBU Nasdaq
- AGIO Nasdaq
- Market Cap
- BBU 2.8B
- AGIO 2.5B
- IPO Year
- BBU N/A
- AGIO 2013
- Fundamental
- Price
- BBU $33.67
- AGIO $29.09
- Analyst Decision
- BBU Buy
- AGIO Buy
- Analyst Count
- BBU 6
- AGIO 9
- Target Price
- BBU $34.67
- AGIO $32.13
- AVG Volume (30 Days)
- BBU 60.5K
- AGIO 2.3M
- Earning Date
- BBU 11-06-2025
- AGIO 10-30-2025
- Dividend Yield
- BBU 0.75%
- AGIO N/A
- EPS Growth
- BBU N/A
- AGIO N/A
- EPS
- BBU N/A
- AGIO N/A
- Revenue
- BBU $27,790,000,000.00
- AGIO $44,791,000.00
- Revenue This Year
- BBU N/A
- AGIO $25.57
- Revenue Next Year
- BBU $5.85
- AGIO $153.24
- P/E Ratio
- BBU N/A
- AGIO N/A
- Revenue Growth
- BBU N/A
- AGIO 36.26
- 52 Week Low
- BBU $18.63
- AGIO $22.24
- 52 Week High
- BBU $36.90
- AGIO $62.45
- Technical
- Relative Strength Index (RSI)
- BBU 55.90
- AGIO 36.49
- Support Level
- BBU $30.91
- AGIO $23.00
- Resistance Level
- BBU $34.39
- AGIO $25.98
- Average True Range (ATR)
- BBU 1.55
- AGIO 2.23
- MACD
- BBU 0.10
- AGIO -1.57
- Stochastic Oscillator
- BBU 85.96
- AGIO 29.12
About BBU Brookfield Business Partners L.P. Limited Partnership Units
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.